Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatorenal Syndrome

Hepatorenal Syndrome

Part of Kidney Diseases

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatorenal Syndrome

4 trials tracked for Hepatorenal Syndrome: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 100 citations.

4Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1
  1. Phase 3 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed · 100 cited
  2. Phase 3 Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Completed · 39 cited
  3. Phase 3 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) Completed
  4. Phase 2 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Observational study links semaglutide dose and weight loss to lower liver disease risk
Diabetes & Endocrinology
Observational study links semaglutide dose and weight loss to lower liver disease risk Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease.
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
medRxiv Apr 19, 2026
Continuous terlipressin infusion reduces treatment failure and rebleeding in acute variceal bleeding
Gastroenterology Meta-analysis
Continuous terlipressin infusion reduces treatment failure and rebleeding in acute variceal bleeding Could a different way of giving a bleeding drug save more lives?
A meta-analysis of 6 RCTs (n=494) in cirrhosis patients found continuous terlipressin infusion reduced treatment failure (RR 0.32) and reble…
A slow drip of the bleeding drug terlipressin works better than a quick shot, causing fewer side effects and less rebleeding for patients wi…
Apr 3, 2026
Case report: Liver transplant recipient on dialysis for over 10 months recovered kidney function
Nephrology
Case report: Liver transplant recipient on dialysis for over 10 months recovered kidney function Can a transplanted liver help a failing kidney recover after months on dialysis?
A case report describes a single liver transplant recipient with pre-transplantation acute kidney injury attributed to hepatorenal syndrome …
A patient on dialysis for over 10 months recovered kidney function after a liver transplant, challenging the belief that long-term dialysis …
Frontiers Mar 31, 2026

Questions about Hepatorenal Syndrome

Can a patient recover kidney function after a liver transplant for hepatorenal syndrome?

Some patients recover kidney function after a liver transplant for hepatorenal syndrome, but dependence on dialysis for over six months lowers the chances of recovery.

Full answer →
Will losing weight with semaglutide lower my risk of liver disease?

Yes, losing weight with semaglutide may lower your risk of liver disease, as weight loss is linked to improvements in fatty liver disease and liver inflammation.

Full answer →